Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
3 ASX Stocks in Focus as Healthcare Growth, Titanium Expansion and Director Buying Drive Attention
Highlights:
Australian stocks attracted attention on 29 October 2026 as developments across biotechnology, advanced titanium manufacturing and financial technology came into focus. Quarterly operating updates highlighted stronger revenue and improved cash outflows in the healthcare sector, increased titanium production capacity alongside US government-backed manufacturing work, and a share purchase by a director of a listed payments company. These developments provide investors with fresh information on business performance, operational progress and director activity.
Stocks in Focus:
Mesoblast Reports Revenue Growth and Lower Cash Outflow
Mesoblast Limited reported its first-quarter FY2027 results on 29 October 2026, with net revenue from RYONCIL increasing 44% year-on-year to US$28 million. The company also reduced its net operating cash spend by 86% to US$2.1 million, compared with US$14.9 million in the corresponding period last year. Cash reserves stood at US$99 million at 30 September 2026. Operationally, Mesoblast completed treatment of all enrolled patients in its Phase 3 trial of rexlemestrocel-L for chronic inflammatory low back pain, with the primary results expected next year. The company also reported a positive meeting with the US Food and Drug Administration regarding a planned biologics licence application for treating life-threatening gastrointestinal bleeding in certain patients with advanced heart failure.
Titanium Expansion Gains Momentum
IperionX Limited released its September 2026 quarterly report on 29 October 2026, reporting titanium powder production of 8.7 tonnes, up from 1.4 tonnes in the previous quarter. Its HAMR™ furnace demonstrated capacity above the targeted 200 tonnes per annum, while its GenX™ continuous production technology achieved six times the throughput of batch processing with more than 75% lower power consumption. The company also received an US$18.5 million US Army Task Order 2 award, including US$11.5 million in initial funding, to support manufacturing expansion and titanium component production. Cash stood at US$63 million at quarter-end, with additional reimbursable government funding of US$33.7 million.
Director Acquires Shares in Payments Company
ZIP Co Limited disclosed a change in director Sarah Adam-Gedge’s indirect shareholding, following an on-market purchase on 27 October 2026. The notice recorded the acquisition of 61,750 fully paid ordinary shares for a total consideration of AU$100,035, held indirectly through an AustralianSuper member account. Her disclosed holding following the transaction was 61,750 shares, with no securities disposed of as part of the reported change. The notice provides details of the director’s share purchase but does not state a reason for the transaction.
Market Outlook
The three announcements highlight different developments across healthcare, advanced manufacturing and financial technology. Investors will be watching for further clinical and commercial progress from the biotechnology business, execution of titanium production and defence manufacturing programmes, and subsequent disclosures regarding director interests and company performance. The share prices cited above reflect the market data supplied for this article and do not establish the cause of each stock's movement.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au